Medicare Benefits Schedule - Item 73316

Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies

Fee: $780.00 Benefit: 75% = $585.00 85% = $681.30

(See para PN.7.20 of explanatory notes to this Category)

• Previous - Item 73315
• Next - Item 73317

The number of measurable residual disease (MRD) tests per patient, per episode of disease or per relapse is not expected to exceed 12, inclusive of a baseline assessment.

Related Items: 73313 73316